
Epizyme Inc (NASDAQ:EPZM) shares are trading higher Monday after the company announced it entered into a definitive agreement to be acquired by Ipsen.
"We expect that this acquisition and Ipsen's commitment to invest in the oncology space will ensure our epigenetic pipeline continues to advance in a way we could not have done on our own to bring transformative cancer therapies to patients in need," said Grant Bogle, president and CEO of Epizyme.